183293-82-5

Usage

Uses

Atherosclerosis therapy; treatment of lipoprotein disorders.

InChI:InChI=1/C16H30O5/c1-15(2,13(17)18)9-5-7-11-21-12-8-6-10-16(3,4)14(19)20/h5-12H2,1-4H3,(H,17,18)(H,19,20)

Upstream product

• 6334-96-9 bis-(4-chlorobutyl)ether 
• 802294-64-0 propionic acid 
• 79-31-2 isobutyric Acid 
• 1276125-68-8 6-iodo-2,2-dimethylhexanoic acid t-butyl ester 
• 851268-15-0 6-bromo-2,2-dimethylhexanoic acid tertbutyl ester 
• 183293-88-1 6-(5-ethoxycarbonyl-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid ethyl ester 
• 88420-48-8 1-iodo-4-(4-iodobutoxy)butane 

Downstream Products

• 863292-21-1 (2S,3S,4S,5R,6S)-6-[(6-{[5-(benzyloxycarbonyl)-5-methylhexyl]oxy}-2,2-dimethylhexanoyl)oxy]-3,4,5-triacetoxytetrahydropyran-2-carboxylic acid benzyl ester 
• 863292-16-4 (2S,3S,4S,5R,6S)-6-[(6-{[5-(benzyloxycarbonyl)-5-methylhexyl]oxy}-2,2-dimethylhexanoyl)oxy]-3,4,5-triacetoxytetrahydropyran-2-carboxylic acid methyl ester 
• 863292-18-6 (2S,3S,4S,5R,6S)-6-[(6-{[5-(benzyloxycarbonyl)-5-methylhexyl]oxy}-2,2-dimethylhexanoyl)oxy]-3,4,5-trihydroxytetrahydropyran-2-carboxylic acid methyl ester 
• 863292-15-3 (2S,3S,4S,5R,6S)-6-[(6-{[5-(benzyloxycarbonyl)-5-methylhexyl]oxy}-2,2-dimethylhexanoyl)oxy]-3,4,5-trihydroxytetrahydropyran-2-carboxylic acid 

Relevant academic research and scientific papers

GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR

This present invention provides gemcabene pharmaceutically acceptable salts having a PSD90 of 35 μm to about 90 μm, methods for purifying crude gemcabene, pharmaceutically acceptable salts of purified gemcabene, pharmaceutical compositions of a gemcabene pharmaceutically acceptable salt and therapeutic and prophylactic methods useful for various conditions, including dyslipidemia.

PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS

The present disclosure provides a process for the preparation of compounds of formula (III), compounds of formula (V), and corresponding salts of formula (IV). The compounds made by the methods and processes of the invention are particularly useful for ad

Carnitine Conjugates As Dual Prodrugs, Methods Of Production And Uses Thereof

The present invention discloses novel dual prodrug compounds of formula (1), methods for their preparation and intermediates in their syntheses, formula (1): wherein A is a single bond, —O—, or —CH2—; m and n vary independently and are an integ

CARNITINE CONJUGATES AS DUAL PRODRUGS, METHODS OF PRODUCTION AND USES THEREOF

The present invention discloses novel dual prodrug compounds of formula (1), methods for their preparation and intermediates in their syntheses, formula (1): wherein A is a single bond, -0-, or -CH2-; m and n vary independently and are an integer from 1 to 15; p and q vary from 0 to an integer from 1 to 4; B is a single bond or -CR3R4; D is formula (2): or formula (3): and X is halogen; R1 to R4 are various substituents selected to optimize the physiochemical and biological properties such as, lipophilicity, bioavailability, and pharmacokinetics of compounds of Formula 1; and R1 and R2 or R3 and R4 may optionally be tethered together to form a 3- to 7-membered alicyclic ring. These compounds are useful for the treatment of various infections, metabolic, cardiovascular and neurological disorders.

Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith

Alcohol and water solvates of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexonoic acid monocalcium salt are crystalline and have the formula (I), wherein R1 is H or lower alkyl, and x is a number from 0 to 10, and are useful for treating dyslipidemia.